BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Yu J, Liang P, Yu X, Cheng Z, Han Z, Duan S, Zheng J. Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results. Oncotarget 2017;8:79742-9. [PMID: 29108354 DOI: 10.18632/oncotarget.19275] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
2 Shen JD, Fu SZ, Ju LL, Wang YF, Dai F, Liu ZX, Ji HZ, Shao JG, Bian ZL. High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:7362-8. [PMID: 29725449 DOI: 10.3892/ol.2018.8189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Qi Y, Hou Y, Qi L. miR-30d-5p represses the proliferation, migration, and invasion of lung squamous cell carcinoma via targeting DBF4. J Environ Sci Health C Toxicol Carcinog 2021;:1-18. [PMID: 34165043 DOI: 10.1080/26896583.2021.1926855] [Reference Citation Analysis]
4 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
5 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016; 7(3): 242-255 [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
6 Kamali C, Kamali K, Brunnbauer P, Splith K, Pratschke J, Schmelzle M, Krenzien F. Extended liver resection in mice: state of the art and pitfalls-a systematic review. Eur J Med Res 2021;26:6. [PMID: 33422147 DOI: 10.1186/s40001-020-00478-3] [Reference Citation Analysis]
7 Meng X, Lu P, Fan Q. miR-367 promotes proliferation and invasion of hepatocellular carcinoma cells by negatively regulating PTEN. Biochem Biophys Res Commun 2016;470:187-91. [PMID: 26772880 DOI: 10.1016/j.bbrc.2016.01.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
8 Salvati E, Stellacci F, Krol S. Nanosensors for early cancer detection and for therapeutic drug monitoring. Nanomedicine 2015;10:3495-512. [DOI: 10.2217/nnm.15.180] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
9 Ziogas IA, Tsoulfas G. Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma. World J Gastrointest Surg 2017; 9(12): 233-245 [PMID: 29359029 DOI: 10.4240/wjgs.v9.i12.233] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
10 Liu X, Wang Z, Chen Z, Liu L, Ma L, Dong L, Zhang Z, Zhang S, Yang L, Shi J, Fan J, Wang X, Gao Q. Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Oncol Res 2018;26:231-9. [PMID: 28911342 DOI: 10.3727/096504017X15051752095738] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
11 Huang H, Bu Y, Zhang X, Liu J, Zhu L, Fang Y. LINC01433 promotes hepatocellular carcinoma progression via modulating the miR‐1301/STAT3 axis. J Cell Physiol 2019;234:6116-24. [DOI: 10.1002/jcp.27366] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
12 Meier M, Andersen KJ, Knudsen AR, Nyengaard JR, Hamilton-Dutoit S, Mortensen FV. Liver regeneration is dependent on the extent of hepatectomy. J Surg Res. 2016;205:76-84. [PMID: 27621002 DOI: 10.1016/j.jss.2016.06.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
13 Gong QZ, Xiao D, Gong GY, Xu J, Wen XD, Feng F, Qu W. EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway. Curr Cancer Drug Targets 2019;19:583-93. [PMID: 30585547 DOI: 10.2174/1568009619666181226094814] [Reference Citation Analysis]
14 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
15 Yi PS, Wang H, Li JS. Evolution and current status of the subclassification of intermediate hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(3): 85-92 [PMID: 32218891 DOI: 10.4240/wjgs.v12.i3.85] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Sequera C, Manzano S, Guerrero C, Porras A. How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma. Hepat Oncol 2018;5:HEP05. [PMID: 30302196 DOI: 10.2217/hep-2017-0026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
17 Makita Y, Murata S, Katou Y, Kikuchi K, Uejima H, Teratani M, Hoashi Y, Kenjo E, Matsumoto S, Nogami M, Otake K, Kawamata Y. Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma. Biochem Biophys Res Commun 2017;493:800-6. [PMID: 28843857 DOI: 10.1016/j.bbrc.2017.08.088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
18 Waidely E, Al-youbi AO, Bashammakh AS, El-shahawi MS, Leblanc RM. Alpha- l -Fucosidase Immunoassay for Early Detection of Hepatocellular Carcinoma. Anal Chem 2017;89:9459-66. [DOI: 10.1021/acs.analchem.7b02284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Thein HH, Qiao Y, Young SK, Zarin W, Yoshida EM, de Oliveira C, Earle CC. Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study. Curr Oncol 2016;23:e196-220. [PMID: 27330357 DOI: 10.3747/co.23.2956] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
20 Hu J, Zhang J, Sun F, Qi M, Su P, Liu H, Gao L, Jiao M, Wu Z, Xiang L, Han B. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor. Anticancer Drugs 2019;30:e0746. [PMID: 31305292 DOI: 10.1097/CAD.0000000000000746] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
21 Xie C, Tiede C, Zhang X, Wang C, Li Z, Xu X, McPherson MJ, Tomlinson DC, Xu W. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Sci Rep 2017;7:9608. [PMID: 28852111 DOI: 10.1038/s41598-017-10083-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
22 Weng S, Zhou L, Deng Q, Wang J, Yu Y, Zhu J, Yuan Y. Niclosamide induced cell apoptosis via upregulation of ATF3 and activation of PERK in Hepatocellular carcinoma cells. BMC Gastroenterol 2016;16:25. [PMID: 26917416 DOI: 10.1186/s12876-016-0442-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
23 Waidely E, Al-youbi AO, Bashammakh AS, El-shahawi MS, Leblanc RM. Study of the Alpha- l -Fucosidase Langmuir Monolayer at the Air–Water Interface. J Phys Chem B 2016;120:12843-9. [DOI: 10.1021/acs.jpcb.6b09094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Wang L, Ding Q, Zhao L, Pan Y, Song Z, Qin Y, Yan X. Decreased BMP-7 and p-Smad1/5/8 expression, and increased levels of gremlin in hepatocellular carcinoma. Oncol Lett 2018;16:2113-8. [PMID: 30008908 DOI: 10.3892/ol.2018.8918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. Br J Cancer. 2017;116:1027-1036. [PMID: 28267710 DOI: 10.1038/bjc.2017.55] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
26 Xu Y, Zheng Y, Liu H, Li T. Modulation of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of hepatocellular carcinoma cells via MAPK signaling transduction. Int J Oncol. 2017;51:791-800. [PMID: 28677801 DOI: 10.3892/ijo.2017.4066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
27 Zhong L, Hou C, Zhang L, Zhao J, Li F, Li W. Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers 2019;23:341-50. [DOI: 10.1007/s11030-018-9875-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
28 Xie J, Zhang A, Wang X. Metabolomic applications in hepatocellular carcinoma: toward the exploration of therapeutics and diagnosis through small molecules. RSC Adv 2017;7:17217-26. [DOI: 10.1039/c7ra00698e] [Cited by in Crossref: 13] [Article Influence: 3.3] [Reference Citation Analysis]
29 Tarantino G, Magistri P, Ballarin R, Di Francia R, Berretta M, Di Benedetto F. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016;7:387. [PMID: 27818634 DOI: 10.3389/fphar.2016.00387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
30 Qin X, Hu X, Wu C, Cai M, Li Z, Zhang L, Lin L, Huang W, Zhu K. Hepatocellular Carcinoma Cells Carrying a Multimodality Reporter Gene for Fluorescence, Bioluminescence, and Magnetic Resonance Imaging In Vitro and In Vivo. Academic Radiology 2016;23:1422-30. [DOI: 10.1016/j.acra.2016.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett. 2016;371:171-181. [PMID: 26655273 DOI: 10.1016/j.canlet.2015.11.034] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 14.8] [Reference Citation Analysis]
32 Zhao X, Hao J, Chen S. Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer. Evid Based Complement Alternat Med 2020;2020:6076572. [PMID: 32256653 DOI: 10.1155/2020/6076572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070 [PMID: 26576091 DOI: 10.3748/wjg.v21.i42.12059] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
34 Conte C, Maiolino S, Pellosi DS, Miro A, Ungaro F, Quaglia F. Polymeric Nanoparticles for Cancer Photodynamic Therapy. Top Curr Chem 2016;370:61-112. [PMID: 26589506 DOI: 10.1007/978-3-319-22942-3_3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
35 Zeng H, Hui Y, Qin W, Chen P, Huang L, Zhong W, Lin L, Lv H, Qin X. High-throughput sequencing-based analysis of gene expression of hepatitis B virus infection-associated human hepatocellular carcinoma. Oncol Lett 2020;20:18. [PMID: 32774491 DOI: 10.3892/ol.2020.11879] [Reference Citation Analysis]
36 Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, Iida H, Kitade H, Kwon AH, Nagano H, Wada H, Haji S, Tsukamoto T, Kanazawa A, Takeda Y, Takemura S, Kubo S, Nishio K. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget 2016;7:49091-8. [PMID: 27384874 DOI: 10.18632/oncotarget.10077] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
37 Li B, Mao R, Liu C, Zhang W, Tang Y, Guo Z. LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells. Life Sci 2018;197:122-9. [PMID: 29421439 DOI: 10.1016/j.lfs.2018.02.006] [Cited by in Crossref: 85] [Cited by in F6Publishing: 94] [Article Influence: 28.3] [Reference Citation Analysis]
38 Zhi Y, Abudoureyimu M, Zhou H, Wang T, Feng B, Wang R, Chu X. FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma. Mol Ther Nucleic Acids. 2019;16:576-588. [PMID: 31082791 DOI: 10.1016/j.omtn.2019.04.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
39 Waidely E, Al-Yuobi AR, Bashammakh AS, El-Shahawi MS, Leblanc RM. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016;141:36-44. [PMID: 26606739 DOI: 10.1039/c5an01884f] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
40 Xu B, Xu T, Liu H, Min Q, Wang S, Song Q. MiR-490-5p Suppresses Cell Proliferation and Invasion by Targeting BUB1 in Hepatocellular Carcinoma Cells. Pharmacology 2017;100:269-82. [PMID: 28810242 DOI: 10.1159/000477667] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
41 Jia X, Wei S, Xiong W. CXCL5/NF-κB Pathway as a Therapeutic Target in Hepatocellular Carcinoma Treatment. J Oncol 2021;2021:9919494. [PMID: 34194499 DOI: 10.1155/2021/9919494] [Reference Citation Analysis]
42 Lu M, Kong X, Wang H, Huang G, Ye C, He Z. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 2017;8:8775-84. [PMID: 28060739 DOI: 10.18632/oncotarget.14452] [Cited by in Crossref: 40] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
43 Yang J, Qiu B, Li X, Zhang H, Liu W. p53-p66shc/miR-21-Sod2 signaling is critical for the inhibitory effect of betulinic acid on hepatocellular carcinoma. Toxicology Letters 2015;238:1-10. [DOI: 10.1016/j.toxlet.2015.07.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
44 Liu C, Wang C, Wang J, Huang H. miR-1297 promotes cell proliferation by inhibiting RB1 in liver cancer. Oncol Lett 2016;12:5177-82. [PMID: 28105225 DOI: 10.3892/ol.2016.5326] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
45 Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, Ji M, Lv GY. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis. Clin Chim Acta 2015;448:161-9. [PMID: 26164382 DOI: 10.1016/j.cca.2015.06.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
46 Sun Z, Zhao L, Wang S, Wang H. Knockdown of long non-coding RNA LINC01006 represses the development of hepatocellular carcinoma by modulating the miR-194-5p/CADM1 axis. Ann Hepatol 2021;:100571. [PMID: 34718169 DOI: 10.1016/j.aohep.2021.100571] [Reference Citation Analysis]
47 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
48 Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I, Sheha A, El Gewaity M, Abdel-Rahman O. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Expert Rev Gastroenterol Hepatol 2018;12:99-107. [PMID: 29124987 DOI: 10.1080/17474124.2018.1403898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Ko CY, Shih PC, Huang PW, Lee YH, Chen YF, Tai MH, Liu CH, Wen ZH, Kuo HM. Sinularin, an Anti-Cancer Agent Causing Mitochondria-Modulated Apoptosis and Cytoskeleton Disruption in Human Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3946. [PMID: 33920454 DOI: 10.3390/ijms22083946] [Reference Citation Analysis]
50 Ballarin R, Cucchetti A, Russo FP, Magistri P, Cescon M, Cillo U, Burra P, Pinna AD, Di Benedetto F. Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World J Gastroenterol 2017; 23(12): 2095-2105 [PMID: 28405138 DOI: 10.3748/wjg.v23.i12.2095] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
51 Mintz K, Waidely E, Zhou Y, Peng Z, Al-youbi AO, Bashammakh AS, El-shahawi MS, Leblanc RM. Carbon dots and gold nanoparticles based immunoassay for detection of alpha-L-fucosidase. Analytica Chimica Acta 2018;1041:114-21. [DOI: 10.1016/j.aca.2018.08.055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
52 Li Z, Wang Y. miR-96 targets SOX6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma. Biochem Cell Biol 2018;96:365-71. [DOI: 10.1139/bcb-2017-0183] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
53 Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv 2021;18:489-513. [PMID: 33225771 DOI: 10.1080/17425247.2021.1854223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Nakayama H, Takayama T. Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol 2015; 7(20): 2292-2302 [PMID: 26380653 DOI: 10.4254/wjh.v7.i20.2292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
55 Zhuang PY, Zhang KW, Wang JD, Zhou XP, Liu YB, Quan ZW, Shen J. Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells. Oncotarget 2017;8:77915-27. [PMID: 29100435 DOI: 10.18632/oncotarget.20946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
56 Ruan C, You L, Qiu Y, Cui X, Wu D. Tubeimoside I induces autophagy in HepG2 cells by activating the AMP-activated protein kinase signaling pathway. Oncol Lett 2020;20:623-30. [PMID: 32537027 DOI: 10.3892/ol.2020.11604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Duan S, Yu J, Han Z, Cheng Z, Liang P. Association Between P2RX7 Gene and Hepatocellular Carcinoma Susceptibility: A Case-Control Study in a Chinese Han Population. Med Sci Monit 2016;22:1916-23. [PMID: 27272229 DOI: 10.12659/msm.895763] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
58 Zhang L, Chen J, Gao C, Liu C, Xu K. An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming. Med Biol Eng Comput 2018;56:1771-9. [DOI: 10.1007/s11517-018-1811-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Liang HY, Guo QY, Sun W, Mao XN, Wen F, Shan M, Zhao G, Wang XH, Lu ZM. Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2015;30:427-32. [PMID: 26683133 DOI: 10.1089/cbr.2015.1884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
60 Rice DR, Hyer JM, Diaz A, Pawlik TM. End-of-Life Hospice Use and Medicare Expenditures Among Patients Dying of Hepatocellular Carcinoma. Ann Surg Oncol 2021;28:5414-22. [PMID: 33528708 DOI: 10.1245/s10434-021-09606-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Anyiwe K, Qiao Y, De P, Yoshida EM, Earle CC, Thein H. Effect of socioeconomic status on hepatocellular carcinoma incidence and stage at diagnosis, a population-based cohort study. Liver Int 2016;36:902-10. [DOI: 10.1111/liv.12982] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
62 Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol 2018;25:423-9. [PMID: 29198946 DOI: 10.1016/j.acra.2017.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
63 Ding Q, Tian XG, Li Y, Wang QZ, Zhang CQ. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J Gastroenterol 2015; 21(32): 9566-9576 [PMID: 26327764 DOI: 10.3748/wjg.v21.i32.9566] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
64 Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, Nikolaou K. Imaging of HCC-Current State of the Art. Diagnostics (Basel). 2015;5:513-545. [PMID: 26854169 DOI: 10.3390/diagnostics5040513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
65 Khiewkamrop P, Phunsomboon P, Richert L, Pekthong D, Srisawang P. Epistructured catechins, EGCG and EC facilitate apoptosis induction through targeting de novo lipogenesis pathway in HepG2 cells. Cancer Cell Int 2018;18:46. [PMID: 29588626 DOI: 10.1186/s12935-018-0539-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
66 Chang KP, Lin SH, Chu YW. Artificial intelligence in gastrointestinal radiology: A review with special focus on recent development of magnetic resonance and computed tomography. Artif Intell Gastroenterol 2021; 2(2): 27-41 [DOI: 10.35712/aig.v2.i2.27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Meier M, Knudsen AR, Andersen KJ, Bjerregaard NC, Jensen UB, Mortensen FV. Gene Expression in the Liver Remnant Is Significantly Affected by the Size of Partial Hepatectomy: An Experimental Rat Study. Gene Expr 2017;17:289-99. [PMID: 28488569 DOI: 10.3727/105221617X695825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Ni J, Fu C, Huang R, Li Z, Li S, Cao P, Zhong K, Ge M, Gao Y. Metabolic syndrome cannot mask the changes of faecal microbiota compositions caused by primary hepatocellular carcinoma. Lett Appl Microbiol 2021;73:73-80. [PMID: 33768575 DOI: 10.1111/lam.13477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ahmed W, Mofed D, Zekri AR, El-Sayed N, Rahouma M, Sabet S. Antioxidant activity and apoptotic induction as mechanisms of action of Withania somnifera (Ashwagandha) against a hepatocellular carcinoma cell line. J Int Med Res 2018;46:1358-69. [PMID: 29392963 DOI: 10.1177/0300060517752022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]